美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Nasus Pharma Ltd.

5.60

0.0000

成交量：2,235.00

成交額：1.22萬

市值：5,075.54萬

市盈率：-26.54

高：5.60

開：5.60

低：5.60

收：5.60

52周最高：9.99

52周最低：4.90

股本：906.35萬

流通股本：398.27萬

量比：0.50

換手率：0.06%

股息：- -

股息率：- -

每股收益(TTM):-0.2110

每股收益(LYR):-0.2180

淨資產收益率：--

總資產收益率：-106.39%

市淨率：-11.77

市盈率(LYR):-25.69

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Nasus Pharma完成1500萬美元私募配售定價機構投資者溢價認購

Nasus Pharma Ltd.盤中異動股價大漲10.51%

納斯醫藥：完整二期試驗結果預計2026年第一季度末公布；關鍵研究計劃於2026年第四季度啓動

Nasus Pharma Ltd中期結果顯示Ns002較Epipen吸收更快、峯值濃度更高

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NSRX"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NSRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","market":"US","secType":"STK","nameCN":"Nasus Pharma Ltd.","latestPrice":5.6,"timestamp":1770930000000,"preClose":5.6,"halted":0,"volume":2235,"delay":0,"changeRate":0,"floatShares":3982680,"shares":9063458,"eps":-0.211,"marketStatus":"未開盤","change":0,"latestTime":"02-12 16:00:00 EST","open":5.6,"high":5.6,"low":5.6,"amount":12173.2076,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.211,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1770973200000},"marketStatusCode":0,"adr":0,"listingDate":1755057600000,"exchange":"AMEX","adjPreClose":5.6,"volumeRatio":0.503401},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","floatShares":3982680,"roa":"-106.39%","roe":"--","lyrEps":-0.217993,"volumeRatio":0.503401,"shares":9063458,"dividePrice":0,"high":5.6,"amplitude":0,"preClose":5.6,"low":5.6,"week52Low":4.9,"pbRate":"-11.77","week52High":9.9899,"institutionHeld":0,"latestPrice":5.6,"eps":-0.211,"divideRate":0,"volume":2235,"delay":0,"ttmEps":-0.211,"open":5.6,"prevYearClose":9.15,"prevWeekClose":5.44,"prevMonthClose":5.74,"prevQuarterClose":9.15,"fiveDayClose":5.75,"twentyDayClose":7.1,"sixtyDayClose":7.41},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NSRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NSRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NSRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1766120400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NSRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NSRX","date":"2026-02-11","current":-26.540284,"percent":0.983871,"low":-51.389177,"twenty":-47.348516,"median":-44.351994,"eighty":-35.511272,"high":-25.573457,"avg":-41.456995,"sd":6.760597,"marketCap":49284408},"quantilePoints":[{"date":"2025-08-15","current":-47.343663,"twenty":-48.284655,"median":-47.931783,"eighty":-47.578911,"marketCap":72530491},{"date":"2025-08-22","current":-50.265593,"twenty":-50.691372,"median":-49.082873,"eighty":-48.024103,"marketCap":77006889},{"date":"2025-08-29","current":-47.604473,"twenty":-50.029049,"median":-48.047994,"eighty":-47.509856,"marketCap":72930053},{"date":"2025-09-05","current":-47.370886,"twenty":-49.082873,"median":-47.841017,"eighty":-47.486202,"marketCap":72572198},{"date":"2025-09-12","current":-48.136697,"twenty":-48.519903,"median":-47.66361,"eighty":-47.343663,"marketCap":73745420},{"date":"2025-09-19","current":-47.384488,"twenty":-48.195834,"median":-47.722745,"eighty":-47.36793,"marketCap":72593035},{"date":"2025-09-26","current":-47.604473,"twenty":-48.136697,"median":-47.604473,"eighty":-47.343663,"marketCap":72930053},{"date":"2025-10-03","current":-36.900859,"twenty":-48.077561,"median":-47.51577,"eighty":-47.308794,"marketCap":56532116},{"date":"2025-10-10","current":-45.830394,"twenty":-48.047993,"median":-47.384488,"eighty":-45.830394,"marketCap":70212163},{"date":"2025-10-17","current":-46.835706,"twenty":-47.900153,"median":-47.36793,"eighty":-45.534713,"marketCap":71752301},{"date":"2025-10-24","current":-44.943354,"twenty":-47.900153,"median":-47.314116,"eighty":-44.943354,"marketCap":68853218},{"date":"2025-10-31","current":-46.007802,"twenty":-47.900153,"median":-47.308794,"eighty":-45.239034,"marketCap":70483952},{"date":"2025-11-07","current":-44.647674,"twenty":-47.781881,"median":-47.308794,"eighty":-44.943354,"marketCap":68400236},{"date":"2025-11-14","current":-46.717433,"twenty":-47.722745,"median":-47.22009,"eighty":-44.647674,"marketCap":71571108},{"date":"2025-11-21","current":-41.395195,"twenty":-47.722745,"median":-46.835706,"eighty":-44.351994,"marketCap":63417438},{"date":"2025-11-28","current":-41.395195,"twenty":-47.675437,"median":-46.717433,"eighty":-43.654189,"marketCap":63417438},{"date":"2025-12-05","current":-40.508154,"twenty":-47.6163,"median":-46.155642,"eighty":-42.826285,"marketCap":62058492},{"date":"2025-12-12","current":-38.438395,"twenty":-47.604473,"median":-45.830394,"eighty":-41.395195,"marketCap":58887621},{"date":"2025-12-19","current":-37.669627,"twenty":-47.557164,"median":-45.682553,"eighty":-41.383368,"marketCap":57709868},{"date":"2025-12-26","current":-44.351994,"twenty":-47.509856,"median":-45.298465,"eighty":-41.395195,"marketCap":67947255},{"date":"2026-01-02","current":-43.332802,"twenty":-47.445516,"median":-44.987706,"eighty":-41.359713,"marketCap":82895651},{"date":"2026-01-09","current":-33.62436,"twenty":-47.384488,"median":-44.884218,"eighty":-40.236129,"marketCap":64323401},{"date":"2026-01-16","current":-33.62436,"twenty":-47.379047,"median":-44.647674,"eighty":-40.035066,"marketCap":64323401},{"date":"2026-01-23","current":-31.392839,"twenty":-47.370295,"median":-44.529402,"eighty":-38.570149,"marketCap":60054501},{"date":"2026-01-30","current":-26.473264,"twenty":-47.36793,"median":-44.351994,"eighty":-37.823381,"marketCap":50643354},{"date":"2026-02-06","current":-27.467787,"twenty":-47.363077,"median":-44.351994,"eighty":-35.774424,"marketCap":52545877},{"date":"2026-02-11","current":-25.76289,"twenty":-47.348516,"median":-44.351994,"eighty":-35.511272,"marketCap":49284408}],"updateTime":1770959316581},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NSRX\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1155255765","title":"Nasus Pharma完成1500萬美元私募配售定價 機構投資者溢價認購","url":"https://stock-news.laohu8.com/highlight/detail?id=1155255765","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155255765?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 12:05","pubTimestamp":1770782722,"startTime":"0","endTime":"0","summary":"以色列特拉维夫，2026年2月10日——临床阶段制药企业Nasus Pharma Ltd.今日宣布与多家机构及合格投资者签署证券购买协议，将通过私募配售发行普通股及认股权证，募集资金总额约1500万美元。根据协议条款，Nasus Pharma将合计发行2,695,425股无面值普通股，及可认购最多2,695,425股普通股的认股权证，每股普通股及配套权证的组合认购价格为5.565美元。根据协议，Nasus Pharma承诺向美国证券交易委员会提交注册声明，用于登记私募所发行普通股及权证对应普通股的转售。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4006","BK4585","BK4233","BK4007","BK4588","BK4528","X","UK","BK4516","BK4520","BK4205"],"gpt_icon":0},{"id":"2608361767","title":"Nasus Pharma Ltd.盤中異動 股價大漲10.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608361767","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608361767?lang=zh_tw&edition=fundamental","pubTime":"2026-02-04 04:19","pubTimestamp":1770149957,"startTime":"0","endTime":"0","summary":"北京时间2026年02月04日04时19分，Nasus Pharma Ltd.股票出现异动，股价快速上涨10.51%。截至发稿，该股报6.08美元/股，成交量2962股，换手率0.03%，振幅0.36%。Nasus Pharma Ltd.股票所在的制药行业中，整体跌幅为1.84%。Nasus Pharma Ltd.公司简介：Nasus Pharma Ltd是一家临床阶段的专业制药公司，主要专注于开发用于治疗紧急医疗状况的鼻内药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204041918a478b65a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204041918a478b65a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"1197493557","title":"納斯醫藥：完整二期試驗結果預計2026年第一季度末公布；關鍵研究計劃於2026年第四季度啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1197493557","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197493557?lang=zh_tw&edition=fundamental","pubTime":"2026-01-20 21:05","pubTimestamp":1768914341,"startTime":"0","endTime":"0","summary":"纳斯医药有限公司近日披露了其研发管线的最新进展。根据公司规划，针对其主要在研产品开展的二期临床试验的完整数据，预计将在2026年第一季度末之前获得。此次数据公布将为该疗法的有效性和安全性提供更为全面的评估。\n在获得二期试验结果后，公司进一步计划于2026年第四季度正式启动关键性研究。这一阶段的研究旨在为最终向监管机构提交申请提供核心支持，是药物研发进程中至关重要的一步。上述时间表的推进，标志着纳斯医药的核心产品正向后期临床开发阶段稳步迈进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"1141013689","title":"Nasus Pharma Ltd中期結果顯示Ns002較Epipen吸收更快、峯值濃度更高","url":"https://stock-news.laohu8.com/highlight/detail?id=1141013689","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141013689?lang=zh_tw&edition=fundamental","pubTime":"2026-01-20 21:04","pubTimestamp":1768914293,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd最新公布的中期试验数据显示，其研发的Ns002在药物吸收速度与峰值血药浓度两项关键指标上均显著优于市场主流产品Epipen。实验结果表明，Ns002能够实现更快速的系统性吸收，同时达到更高的血浆峰值水平，这一特性可能为紧急过敏反应治疗提供更高效的临床解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NSRX\",params:#limit:6,delay:false,,,undefined,":[]}}